HIV: latest news - GoINPHARMA
Wednesday, 23 January 2019 - 23:18

HIV

New positive clinical results from ViiV’s (GSK) two-drug HIV therapy

ViiV, a subsidiary of GSK’s, yesterday evening announced results from the Phase III clinical trial Flair, assessing the efficacy of its two-drug (cabotegravir, rilpivirine) therapy on HIV patients. Specifically, the results show that the two-drug regime has the same efficacy…

GSK announces new positive clinical data for two-drug HIV treatment

ViiV Healthcare, a subsidiary of  GlaxoSmithKline’s focusing on HIV, has reported today, before trading started in Europe, results from the Phase III Atlas clinical trial, enrolling 618 patients with HIV, treated with a cabotegravir-rilpivirine injected treatment for 48 weeks. The…

First results from GSK’s combo HIV therapy

ViiV, a subsidiary of  GlaxoSmithKline’s having also Pfizer and Shionogi as shareholders, has reported positive early results from the Phase III Gemini-1 and Gemini-2 clinical trials, enrolling 1,400 patients with HIV, treated with a dolutegravir-lamivudine combo therapy for 48 weeks….

Extensive study on depression and HIV

An increasing number of studies shows interesting links between HIV and depression. Among these, it is worth to mention a 10-year analysis (2005-2015) on 6,000 patients with HIV, with an average age of 44, which has demonstrated that risk of…

Gilead’s Biktarvy (HIV) approved

FDA has granted Gilead approval for its novel drug Biktarvy, for the treatment of HIV. Biktarvy combines the novel inhibitor bictegravir with Gilead’s molecules emtricitabine and tenofovir alafenamide. It is a once-daily treatment–a regimen tested in as many as 4…

The worrisome increase of HIV spread in Russia

The spread of HIV in Russia seems unstoppable, although the Government last year implemented significant measures to control the spread of the disease. Experts expect 100,000 new infections by the end of the year, in contrast with the downward trend…

Solid nanoparticles to improve HIV treatment delivery

The journal Nature Communications published a research conducted at the University of Liverpool dealing with a delivery method of drugs targeting paediatric HIV, by using solid nanoparticles. The researchers focused on lopinavir and on a paediatric formulation of the drug,…